Pharmaceutical drug prices and trends for DESVENLAFAXINE SUCCNT ER

Subscribe to access the full database, or Try for Free
Drug Name	NDC	Price/Unit ($)	Unit	Date
DESVENLAFAXINE SUCCNT ER 50 MG	72888-0143-90	0.46463	EACH	2025-03-19
DESVENLAFAXINE SUCCNT ER 100 MG	00054-0401-13	0.47463	EACH	2025-03-19
DESVENLAFAXINE SUCCNT ER 100 MG	00054-0401-22	0.47463	EACH	2025-03-19
DESVENLAFAXINE SUCCNT ER 100 MG	51991-0312-10	0.47463	EACH	2025-03-19
>Drug Name	>NDC	>Price/Unit ($)	>Unit	>Date

Introduction to Desvenlafaxine Succinate ER

Desvenlafaxine succinate, marketed under the brand name Pristiq, is a serotonin-norepinephrine reuptake inhibitor (SNRI) used primarily for the treatment of major depressive disorder (MDD) and other mental health conditions such as anxiety and fibromyalgia. Here’s a comprehensive analysis of the market and price projections for this medication.

Market Size and Growth Projections

The global desvenlafaxine succinate market has been experiencing significant growth, driven by increasing prevalence of mental health disorders and advancements in pharmaceutical R&D.

As of 2023, the desvenlafaxine succinate market was valued at USD 100 billion and is projected to reach USD 140.71 billion by 2031, growing at a compound annual growth rate (CAGR) of 5% from 2024 to 2031[3].

Market Segmentation

The market is segmented based on several key factors:

Type

The market is categorized into tablets, extended-release tablets, capsules, and injectable forms. Extended-release tablets, such as those of desvenlafaxine succinate, are particularly popular due to their once-daily dosing and improved patient compliance[3].

Application

The primary applications include major depressive disorder treatment, anxiety disorder treatment, fibromyalgia management, neuropathic pain management, and menopausal symptom relief. The effectiveness of desvenlafaxine succinate in treating MDD is a significant driver of market growth[3].

Geographical Regions

The market is analyzed across major regions including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa. Each region provides insights into revenue share, current trends, and future market opportunities[1][3].

Key Drivers of Market Growth

Several factors are driving the growth of the desvenlafaxine succinate market:

Increasing Prevalence of Mental Health Disorders

The rising awareness and prevalence of anxiety and depression globally are increasing the demand for effective therapies like desvenlafaxine succinate[3].

Pharmaceutical R&D Advancements

Continuous innovations in pharmaceutical research and development are broadening the range of available treatments, contributing to market expansion[3].

Expanding Access to Mental Health Services

Globally, there is an increasing access to mental health services, which is driving the uptake of desvenlafaxine succinate and other mental health medications[3].

Patient Compliance

The extended-release formulation of desvenlafaxine succinate improves patient compliance, which is a crucial factor in its market success[4].

Price Analysis

The prices of desvenlafaxine succinate vary based on dosage, quantity, and pharmacy.

Generic vs. Brand Name

The generic version of desvenlafaxine succinate is generally cheaper than the brand name version, Pristiq.
- For example, a 30-day supply of generic desvenlafaxine succinate (50 mg) can cost around $75, while a 14-day supply of Pristiq (50 mg) can cost approximately $225[2][5].

Dosage and Quantity

Prices also vary based on the dosage and quantity of the medication.
- A 30-day supply of desvenlafaxine succinate (50 mg) can range from $75 to $97, while a 90-day supply can range from $272 to $273[2].

Coupons and Patient Assistance Programs

Various coupons, copay cards, and patient assistance programs are available to reduce the cost for patients.
- For instance, the Rexulti Savings Card can help eligible commercially insured patients pay $0 per 30-day supply, with a savings of up to $100 per fill[2].

Competitive Landscape

The desvenlafaxine succinate market is competitive, with several key players:

Major Competitors

Companies like Adroit PharmaChem and Teva are focusing on strategy building and product portfolio expansion to strengthen their market presence[1].

Market Strategies

Pharmaceutical companies are investing in R&D to create new formulations and expand product availability in growing regions, driving competitiveness in the industry[3].

Safety and Efficacy

Desvenlafaxine succinate has demonstrated efficacy, safety, and tolerability in clinical trials:

Clinical Trials

Studies have shown significant improvements in depressive symptoms compared to placebo, with the 50 mg/day dose being as effective as higher doses and having a favorable safety profile[4].

Mechanism of Action

Desvenlafaxine succinate targets both serotonin and norepinephrine, making it an effective treatment option for MDD and other mental health conditions[4].

Regional Analysis

The market is segmented into five major regions, each with its own trends and growth prospects:

North America

This region is a significant market due to high healthcare spending and advanced mental health services[1][3].

Europe

Europe also represents a substantial market, driven by increasing mental health awareness and access to healthcare services[1][3].

Asia-Pacific

The Asia-Pacific region is expected to grow rapidly due to an expanding patient base and increasing investments in healthcare infrastructure[1][3].

South America and Middle East & Africa

These regions are also experiencing growth, though at a slower pace, due to improving healthcare access and rising awareness of mental health issues[1][3].

Future Market Opportunities

The desvenlafaxine succinate market is expected to continue growing due to several factors:

Expanding Indications

Ongoing clinical studies are investigating new indications for desvenlafaxine succinate, which could further expand its market[3].

Innovations in Formulations

Pharmaceutical companies are working on new formulations to improve patient compliance and treatment outcomes, which will drive market growth[3].

Increasing Mental Health Awareness

Rising awareness and reducing stigma around mental health issues will continue to drive the demand for effective treatments like desvenlafaxine succinate[3].

Key Takeaways

The desvenlafaxine succinate market is valued at USD 100 billion in 2023 and is projected to reach USD 140.71 billion by 2031.
The market is driven by increasing prevalence of mental health disorders, advancements in pharmaceutical R&D, and expanding access to mental health services.
The extended-release formulation of desvenlafaxine succinate improves patient compliance and is a key factor in its market success.
Prices vary based on dosage, quantity, and pharmacy, with generic versions generally being cheaper than brand name versions.
Various coupons and patient assistance programs are available to reduce costs for patients.

FAQs

What is desvenlafaxine succinate used for?

Desvenlafaxine succinate is primarily used for the treatment of major depressive disorder (MDD) and other mental health conditions such as anxiety and fibromyalgia.

How much does desvenlafaxine succinate cost?

The cost of desvenlafaxine succinate can vary, but a 30-day supply of the generic version (50 mg) can cost around $75, while a 14-day supply of the brand name version (Pristiq) can cost approximately $225.

Is desvenlafaxine succinate safe and effective?

Yes, desvenlafaxine succinate has demonstrated efficacy, safety, and tolerability in clinical trials, with significant improvements in depressive symptoms compared to placebo and a favorable safety profile.

What are the key drivers of the desvenlafaxine succinate market?

The key drivers include increasing prevalence of mental health disorders, advancements in pharmaceutical R&D, expanding access to mental health services, and innovations in formulations.

Which regions are expected to drive the growth of the desvenlafaxine succinate market?

North America, Europe, and the Asia-Pacific region are expected to be significant drivers of market growth due to high healthcare spending, advanced mental health services, and an expanding patient base.

Are there any patient assistance programs available for desvenlafaxine succinate?

Yes, various coupons, copay cards, and patient assistance programs are available to reduce the cost for patients, such as the Rexulti Savings Card which can help eligible patients pay $0 per 30-day supply.

Sources

Cognitivemarketresearch.com: Desvenlafaxine Market Report 2024 (Global Edition)
Drugs.com: Desvenlafaxine Prices, Coupons, Copay Cards & Patient Assistance
Marketresearchintellect.com: Desvenlafaxine Succinate Market Size and Projections
Psychiatrist.com: Efficacy, Safety, and Tolerability of Desvenlafaxine 50 mg/d for the Treatment of MDD
Drugs.com: Pristiq Prices, Coupons, Copay Cards & Patient Assistance